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Background: Many medical interventions are administered in the form of treatment 
combinations involving two or more individual drugs (eg, drug A + drug B). When the individual 
drugs and drug combinations have been compared in a number of randomized clinical trials, it 
is possible to quantify the comparative effectiveness of all drugs simultaneously in a multiple 
treatment comparison (MTC) meta-analysis. However, current MTC models ignore the 
dependence between drug combinations (eg, A + B) and the individual drugs that are part of 
the combination. In particular, current models ignore the possibility that drug effects may be 
additive, ie, the property that the effect of A and B combined is equal to the sum of the individual 
effects of A and B. Current MTC models may thus be suboptimal for analyzing data including 
drug combinations when their effects are additive or approximately additive. However, the extent 
to which the additivity assumption can be violated before the conventional model becomes the 
more optimal approach is unknown. The objective of this study was to evaluate the comparative 
statistical performance of the conventional MTC model and the additive effects MTC model in 
MTC scenarios where  additivity holds true, is mildly violated, or is strongly violated.
Methods: We simulated MTC scenarios in which additivity held true, was mildly violated, 
or was strongly violated. For each scenario we simulated 500 MTC data sets and applied the 
conventional and additive effects MTC models in a Bayesian framework. Under each scenario 
we estimated the proportion of treatment effect estimates that were 20% larger than ‘the truth’ 
(ie, % overestimates), the proportion that were 20% smaller than ‘the truth’ (ie, % underesti-
mates), the coverage of the 95% credible intervals, and the statistical power. We did this for all 
the comparisons under both models.
Results: Under true additivity, the additive effects model is superior to the conventional model. 
Under mildly violated additivity, the additive model generally yields more overestimates or 
underestimates for a subset of treatment comparisons, but comparable coverage and greater 
power. Under strongly violated additivity, the proportion of overestimates or underestimates 
and coverage is considerably worse with the additive effects model.
Conclusion: The additive MTC model is statistically superior when additivity holds true. 
The two models are comparably advantageous in terms of a bias-precision trade-off when 
additivity is only mildly violated. When additivity is strongly violated, the additive effects 
model is statistically inferior.
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What is known already?
•	 Many treatment combinations are fully additive or close to being fully additive 
(ie, the effect of a treatment combination A + B is equal to the stand-alone effect 
of A plus the stand-alone effect of B)
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•	 Multiple treatment comparison (MTC) meta-analysis 
models are available for comparing the efficacy of 
  multiple treatments in one analysis
•	 The additivity assumption can be incorporated in MTC 
models. These are referred to as “additive effects MTC 
models”.
What is new?
•	 Additive effects MTC models are statistically   superior 
to conventional MTC models (in terms of bias pre-
cision trade-off) even when additivity only holds 
approximately
•	 Additive effects MTC models should not be used when 
clinical data or biological rationale suggests presence of 
a potentially important interaction (ie, lack of additivity) 
or worse
Background
In many fields of medicine, it is often the case that 
interventions are administered to patients in the form of 
treatment combinations involving two or more individual 
drugs (eg, drug A + drug B). Typically, several possible 
combinations of some of the individual drugs will exist, 
and it will therefore be important to assess how each of 
the drugs interact with the other and whether one drug 
combination works better than the other. For instance, if a 
treatment combination includes just two treatments A and B, 
we should use all available randomized clinical trial data 
on each of these treatments to evaluate whether the effect 
of this treatment combination is: equal to the stand-alone 
effect of A plus the stand-alone effect of B; smaller than the 
stand-alone effect of A plus the stand-alone effect of B; or 
larger than the stand-alone effect of A plus the stand-alone 
effect of B. In the first situation, the effect of adding B to A 
is referred to as truly additive. For the second and third 
situations, the effects of adding B to A are referred to as 
antagonistic and synergistic, respectively.1
While the standalone effectiveness of some individual 
drugs may often have been informed by a considerable 
number of randomized clinical trials, the effectiveness 
of the possible combinations of these drugs, let alone 
the comparative effectiveness between the possible drug 
combinations, may only have been informed by a few small 
or no randomized clinical trials. This meta-analytic data 
structure lends itself to analysis with multiple treatment 
comparison (MTC) meta-analysis which allows for 
estimation of comparative effectiveness among all treatments, 
even treatments (drug combinations) that have not been 
compared head-to-head in randomized clinical trials.2–7 In 
contrast with MTCs of stand-alone treatments, many of the 
considered drug combinations include one or more of the 
same drugs (eg, pharmacotherapies for chronic obstructive 
pulmonary disease). This creates a dependence between 
the considered interventions which may be utilized in the 
MTC statistical models to enhance precision.7 Welton et al 
propose and discuss possible MTC approaches for modeling 
treatment combinations based on different assumptions about 
how the treatments interact when combined.7 In particular, 
one can construct different MTC models in which all effects 
are assumed to be fully additive (Welton et al dubbed this 
model the “main additive effects model”), every pair of 
treatments (drugs) may interact (Welton et al dubbed this 
the “two-way interaction model”), or every set of treatments 
may interact (Welton el al dubbed this the “full interaction 
model”). In terms of estimating comparative effects between 
all treatments, the “full interaction model” is identical to the 
conventional MTC model, which would ignore dependence 
between the effectiveness of drug combinations including 
one or more of the same individual drugs.
Because drugs that are used in combination typically 
target different biological pathways, it is reasonable to 
believe that most approved drug combinations are either truly 
or approximately additive. For example, in a recent MTC 
investigating the effects of pharmacotherapies for reducing 
exacerbations among patients with chronic obstructive 
pulmonary disease, the meta-analysis effect estimates for 
single-drug therapies, when added up, seemed congruent 
with meta-analysis effect estimates for the corresponding 
drug combination (eg, the effect of inhaled corticosteroids 
versus placebo and the effect of long-acting bronchodilators 
versus placebo, when added up, matched the effect of the 
two active drugs combined versus placebo, see Table 1).8 
Another source of evidence to suggest that additive treatment 
effects are common is a 2003 review of individual trials 
investigating treatment interactions.1 This review found that 
only 16% of the reviewed trials yielded a “clinically relevant” 
interaction and only 6% detected a statistically significant 
interaction.1 In other words, in 84% of the reviewed trials, 
the effects of the treatments were approximately additive, 
and in 94% of the trials a significant interaction effect could 
not be demonstrated.
Despite the likelihood of additivity or approximate additiv-
ity of treatment effects, the available randomized clinical trial 
data as well as the current understanding of the pharmacology 
of the agents may not suffice to warrant that an assumption of 
additivity be incorporated in the statistical model. The additive 
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effects MTC model facilitates a notable increase in precision if 
the additivity assumptions are correct. However, if the additiv-
ity assumption is incorrect, statistical bias will result for some 
of the involved treatment effect estimates. Thus, there is a need 
to explore how the additive effects MTC model compared 
with the conventional MTC model trades off   precision and 
statistical bias. Therefore, to inform this issue, we performed a 
simulation study comparing the precision (measured as cover-
age and power) and statistical bias (measured as proportion 
of overestimates and underestimates) under the two MTC 
models for scenarios varying from fully additive to strongly 
antagonistic. The objective of this study was to evaluate the 
comparative statistical performance (bias-precision trade-off) 
of the conventional MTC model and the additive effects MTC 
model in MTC scenarios where additivity holds true, where 
there is a mild antagonistic interaction, and where there is a 
strong antagonistic interaction.
Materials and methods
Statistical models
The two statistical models, ie, the conventional MTC model and 
the additive effects MTC model, have the following setup.
Model 1: conventional MTC model
Let k denote any active treatment and let b denote some 
  reference treatment (eg, placebo). Let θjk denote the measured 
effect on the desired modeling scale (eg, log-odds) in the 
treatment arm with treatment k in trial j. Let δjk denote 
the trial-level comparative treatment effect (eg, log odds 
ratio [OR]) of treatment k versus treatment b in trial j. Let 
dk denote the overall treatment effect of treatment k versus b. 
The comparative treatment effects in the treatment network 
are then modeled as follows:
θjk = µj + δjbk ⋅ 1[k>b]
δjbk ∼ N(dk, σbk
2)
dhk = dk − dh
where µj denotes the study-level baseline effect which 
is regarded as a nuisance parameter, where σbk
2 is the 
between-trial variance associated with dk, and where 
dhk is the overall comparative effect of treatment k versus 
treatment h. With this setup, treatment combinations are 
modeled as unrelated to the individual treatment they are 
made up of. For example, with three individual treatments, 
A, B, and C, and four possible treatment combinations 
Table 1 Motivating example of consistency between additive effects directly investigated in clinical trials and additive effects obtained 
using an adjusted indirect approach
Direct comparison Direct additive effects Identical direct or indirect comparison under the additivity 
assumption*
Trials  
(n)
Patients  
(n)
Rate ratio  
(95% CI)
Identical  
comparison
Trials  
(n)
Patients  
(n)
Rate ratio 
(95% CI)
Single direct effect estimates
rOF versus placebo 3 6015 0.85 (0.78–0.93) – – – –
LABA versus placebo 6 6134 0.87 (0.79–0.96) – – – –
LAMA versus placebo 6 10,689 0.74 (0.64–0.84) – – – –
iCS versus placebo 6 5732 0.81 (0.74–0.90) – – – –
Additive effects related to single direct effect estimates
rOF + LABA versus LABA 1 931 0.79 (0.70–0.91) rOF versus placebo 3 6015 0.85 (0.78–0.93)
iCS + LABA versus LABA 7 6860 0.81 (0.75–0.86) iCS versus placebo 6 5732 0.81 (0.74–0.90)
rOF + LAMA versus LAMA 1 743 0.83 (0.72–0.97) rOF versus placebo 3 6015 0.85 (0.78–0.93)
LABA + LAMA versus LAMA 1 304 1.07 (0.94–1.22) LABA versus placebo 6 6134 0.87 (0.79–0.96)
iCS + LABA + LAMA versus  
LABA + LAMA
1 293 0.85 (0.74–0.97) iCS versus placebo 6 5732 0.81 (0.74–0.90)
Additive effects related to indirect effect estimates
iCS + LABA versus placebo 4 4509 0.72 (0.66–0.79) iCS versus placebo +  
LABA versus placebo
11 11,866 0.70 (0.61–0.81)
iCS + LABA + LAMA  
versus LAMA
1 301 0.91 (0.75–1.11) iCS versus placebo +  
LABA versus placebo
11 11,866 0.70 (0.61–0.81)
iCS + LABA versus LAMA 1 1323 0.97 (0.93–1.02) iCS + LABA versus  
placebo + LAMA versus 
placebo
10 15,159 0.95 (0.78–1.16)
Notes: The example presents the effects of four pharmacotherapies, ie, roflumilast, long-acting bronchodilators, long-acting muscarinic agents, and inhaled corticosteroids, 
for chronic obstructive pulmonary disease from a recent multiple treatment comparison. The effect is measured as a ratio of incidence rates of exacerbations. *Under the 
additivity assumption the comparative effect of A + B versus A is identical to the effect of B versus placebo.
Abbreviations: CI, confidence interval; ROF, roflumilast; LABA, long-acting bronchodilators; LAMA, long-acting muscarinic agents; ICS, inhaled corticosteroids.
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hereof, A + B, A + C, B + C, and A + B + C, all seven are 
treated as distinct.
Model 2: additive effects MTC model
Under the additive effects MTC model, the effects of the 
  individual treatments are modeled both as individual   treatments 
and through the effects of treatment combinations assuming 
additivity. Treatment k is either a stand-alone treatment or a 
combination of a set of the considered treatments, eg, A, B, C. 
Mathematically, we let X ⊂ k denote that the treatment X is 
part of the treatment combination that makes up treatment k 
(note that X can also be the only treatment that is, if treatment 
k is a stand-alone treatment). Under the additive effects model, 
the treatment effect of k (versus some reference treatment b), 
dk, is modeled as follows:7
  dk = dA ⋅	1[A ⊂ k] + dB ⋅	1[B ⊂ k] + dC ⋅	1[C ⊂ k] + …
The remaining parameters are modeled as in model 1, ie, 
the conventional MTC model.
Simulation setup
We were primarily interested in the three scenarios: the 
two treatments are completely additive, so adding B to A 
provides the same relative benefit as adding B to nothing (ie, 
placebo, P); the two treatments produce a mild but potentially 
relevant antagonistic interaction, so adding B to A provides 
a smaller relative benefit than adding B to nothing; the two 
treatments produce a strong antagonistic interaction, so adding 
B to A is the same as adding nothing to A. In the first situation 
the OR of the effect of A + B (compared with placebo), 
ie, ORA+B,P, is simply equal to the OR for A, ORA,P, multiplied 
by the OR of B, ORB,P. In the second and third situations 
(and in a setting where the interaction is synergistic) ORA+B,P 
is equal to the same product, but additionally multiplied by 
some interaction ratio, IRAB, that indicates the magnitude with 
which the interaction is antagonistic or synergistic.1
ORA+B,P = ORA,P * ORB,P * IRAB  
  (ie, log[ORA+B,P] = log[ORA,P] + log[ORB,P] + log[IRAB])
For all simulations, we set the true treatment effects of 
A versus P and B versus P, expressed as OR to ORA = 1.40 
and ORB = 1.20. For the first situation, where the two 
treatments are completely additive, ORA+B,P = 1.68 (and the 
corresponding IRAB is equal to 1). For the second situation, we 
considered ORA+B,P = 1.50 as an appropriate representation of 
the two treatments producing a mild but potentially relevant 
antagonistic interaction (in this situation the corresponding 
IRAB is equal to 0.890). For the third situation, we considered 
ORA+B,P = 1.40 as an appropriate representation of the two 
treatments producing a strong antagonistic interaction (in 
this situation the corresponding IRAB is equal to 0.833). We 
did not consider synergistic interactions since we do not 
believe these occur frequently with modern day treatment 
comparisons.
As shown in Figure 1, we simulated four different treat-
ment networks:
•	 a full completely connected network
•	 a “square” network, including the four comparisons 
P versus A, P versus B, A versus A + B, and B versus 
A + B
•	 a “horseshoe” network, including the three comparisons 
P versus A, P versus B, and A versus A + B
•	 a “star” network including the three comparisons 
P   versus A, P versus B, and P versus A + B.
These four networks were specifically chosen as they 
were highly represented in two recent respirology MTCs.8,9 
For all simulations, we simulated five two-arm trials for all 
included comparisons in the network. We simulated trial 
sample sizes by sampling the trial sample size with equal 
probability from all integers between 100 and 500 and 
between 500 and 1500. The number of patients in each inter-
vention arm was set to half of the trial sample size (rounded 
up if the trial sample size was an odd number). These sample 
sizes were based on observations of subtreatment networks 
of two recent respirology MTCs.8,9 For all simulations, we 
assumed an average control group risk of 40%, and sampled 
the realized trial control group risk from a uniform distribu-
tion between 30% and 50%. For all simulations, we assumed 
AB
CD
A A + B
P B
A A + B
P B
A A + B
P B
A A + B
P B
Figure  1  Four  networks  of  treatments  considered  in  our  simulation  study,  ie, 
(A) the full network, (B) the “square” network, (C) the “horseshoe” network, and 
(D) the “star” network.
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a “common” heterogeneity   variance on the log OR scale of 
0.10 for all comparisons. Again, the chosen parameter values 
and parameter value ranges were extrapolated from recent 
respirology MTCs, and were selected to create a “com-
mon” yet generalizable set of MTC scenarios.8,9 In total, we 
simulated combinations of four different network structures, 
two different trial sample size distributions, and three dif-
ferent interactions of A and B. Thus, we simulated a total 
of 24 scenarios.
Models and simulation technicalities
All simulations were run from R. v.2.12.10 Each MTC data 
set was simulated (created) from R, and BRUGS was used to 
analyze each of the simulated data sets with the considered 
MTC models through WinBUGS.11 For each simulated 
MTC data set, we used the conventional MTC model (model 
1) in which all treatments are assumed to be completely 
independent, and the additive effects MTC model (model 
2) in which treatment effects are assumed to be fully additive. 
For each scenario, we first simulated five test data sets and 
checked convergence of all treatment effect parameters and 
between-trial variance parameters using the Gelman–Rubin 
convergence diagnostics.12 Convergence consistently 
appeared to occur before 10,000 iterations. However, to 
increase our confidence that convergence had occurred, we 
decided to use a burn-in of 20,000 iterations. Inferences were 
subsequently based on 10,000 iterations. For each scenario 
we simulated 500 data sets.
Analysis of simulated data
For all 24 simulation scenarios we calculated:
•	 the proportion of estimates of ORA,P, ORB,P, ORA+B,P, and 
ORA+B,A that were 20% relatively greater or smaller than the 
true parameter value. We believe the 20% threshold repre-
sents a clinically important overestimate or underestimate
•	 the coverage of the 95% credible intervals associated 
with each of the above OR estimates
•	 the power associated with each of the above OR estimates 
(we considered 95% credible intervals that did not include 
an OR of 1.00 as statistical evidence of effect).
Table 2 Proportion of overestimates for comparative intervention effect estimates (odds ratio estimates) of A versus P (OrA,P), 
B versus P (OrB,P), A + B versus P (OrA+B,P), and A + B versus A (OrA+B,A) under the two MTC models
Network  
type
Trial  
sample size
Interaction Proportion of overestimates
Conventional MTC model (model 1) Additive MTC model (model 2)
ORA,P ORB,P ORA+B,P ORA+B,A ORA,P ORB,P ORA+B,P ORA+B,A
Full 50–500 Strong antagonistic 11.2% 10.8% 9.8% 0.8% 0.4% 0.6% 9.2% 0.6%
Full 50–500 Mild antagonistic 12.2% 10.6% 11.2% 15.0% 4.5% 2.0% 10.8% 16.0%
Full 50–500 Additive 12.2% 12.6% 10.6% 12.6% 5.4% 5.6% 10.8% 5.6%
Full 500–1500 Strong antagonistic 9.0% 5.8% 6.4% 0.2% 0.4% 0.4% 6.4% 0.4%
Full 500–1500 Mild antagonistic 5.6% 7.0% 6.4% 3.6% 0.6% 0.4% 6.6% 0.4%
Full 500–1500 Additive 9.6% 9.4% 8.4% 11.6% 3.0% 5.2% 8.2% 5.2%
Square 50–500 Strong antagonistic 13.6% 15.2% 19.8% 17.8% 3.0% 3.0% 20.0% 28.0%
Square 50–500 Mild antagonistic 15.8% 15.4% 15.4% 14.0% 4.6% 4.8% 15.6% 17.8%
Square 50–500 Additive 18.8% 15.6% 23.0% 17.0% 10.8% 12.4% 22.8% 12.4%
Square 500–1500 Strong antagonistic 10.8% 9.4% 17.4% 15.6% 2.2% 1.8% 17.4% 27.0%
Square 500–1500 Mild antagonistic 9.4% 13.2% 17.4% 14.8% 3.2% 3.2% 17.6% 18.6%
Square 500–1500 Additive 11.0% 9.6% 14.8% 14.8% 8.6% 8.6% 15.0% 8.6%
Horseshoe 50–500 Strong antagonistic 18.0% 18.4% 26.8% 21.8% 18.2% 4.8% 34.6% 28.6%
Horseshoe 50–500 Mild antagonistic 17.8% 14.4% 28.0% 20.8% 18.0% 4.4% 31.4% 18.2%
Horseshoe 50–500 Additive 14.2% 16.8% 26.4% 21.2% 14.8% 11.0% 22.8% 11.0%
Horseshoe 500–1500 Strong antagonistic 11.6% 13.2% 24.2% 20.4% 11.8% 1.4% 34.6% 26.8%
Horseshoe 500–1500 Mild antagonistic 12.0% 10.2% 23.4% 20.2% 12.0% 2.6% 25.6% 24.2%
Horseshoe 500–1500 Additive 12.0% 9.8% 24.2% 20.6% 11.2% 8.2% 17.8% 8.2%
Star 50–500 Strong antagonistic 14.0% 16.4% 12.8% 24.8% 3.4% 5.4% 21.0% 31.2%
Star 50–500 Mild antagonistic 16.2% 17.4% 14.4% 12.4% 8.6% 8.2% 16.4% 8.2%
Star 50–500 Additive 17.4% 17.8% 19.0% 25.0% 12.8% 11.6% 15.6% 11.6%
Star 500–1500 Strong antagonistic 11.2% 12.2% 12.0% 21.0% 1.4% 1.4% 18.2% 33.6%
Star 500–1500 Mild antagonistic 11.4% 9.2% 12.0% 21.2% 4.8% 3.4% 11.6% 19.0%
Star 500–1500 Additive 12.0% 11.4% 11.0% 21.0% 6.4% 7.0% 8.0% 7.0%
Notes: The first three columns indicate which of the 16 simulation scenarios the results on the corresponding row are representative of; columns 4 to 7 present the 
proportion of overestimates under the conventional MTC model for each of the abovementioned four comparative effects. Columns 8 to 11 present the proportion of 
overestimates under the fully additive MTC model.
Abbreviations: MTC, multiple treatment comparison; OR, odds ratio.
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Table 3 Proportion of underestimates for comparative intervention effect estimates (odds ratio estimates) of A versus P (OrA,P), 
B versus P (OrB,P), A + B versus P (OrA+B,P), and A + B versus A (OrA+B,A) under the two MTC models
Network  
type
Trial  
sample size
Interaction Proportion of underestimates
Conventional MTC model (model 1) Additive MTC model (model 2)
ORA,P ORB,P ORA+B,P ORA+B,A ORA,P ORB,P ORA+B,P ORA+B,A
Full 50–500 Strong antagonistic 8.2% 10.8% 7.6% 12.2% 18.0% 19.4% 8.0% 1.0%
Full 50–500 Mild antagonistic 10.2% 11.2% 8.6% 13.0% 10.4% 13.8% 8.8% 1.6%
Full 50–500 Additive 10.4% 8.0% 8.4% 13.2% 5.6% 4.4% 8.4% 4.4%
Full 500–1500 Strong antagonistic 4.8% 6.2% 5.0% 11.0% 15.4% 18.8% 5.4% 0.8%
Full 500–1500 Mild antagonistic 10.2% 5.8% 6.8% 10.4% 12.6% 11.4% 6.8% 0.6%
Full 500–1500 Additive 8.4% 7.6% 5.2% 11.2% 2.8% 4.8% 5.2% 4.8%
Square 50–500 Strong antagonistic 13.6% 13.6% 18.2% 16.8% 27.0% 26.2% 17.8% 3.0%
Square 50–500 Mild antagonistic 12.4% 13.6% 15.4% 21.0% 16.0% 20.0% 15.2% 5.0%
Square 50–500 Additive 11.0% 13.2% 18.4% 20.8% 11.4% 12.6% 18.6% 12.8%
Square 500–1500 Strong antagonistic 10.2% 10.2% 15.4% 15.6% 23.0% 26.2% 15.6% 1.8%
Square 500–1500 Mild antagonistic 9.4% 8.2% 14.0% 12.6% 16.6% 13.2% 13.6% 2.8%
Square 500–1500 Additive 9.6% 9.0% 14.4% 14.8% 7.2% 7.2% 14.0% 7.2%
Horseshoe 50–500 Strong antagonistic 14.6% 18.8% 22.4% 17.6% 14.6% 25.8% 12.4% 3.2%
Horseshoe 50–500 Mild antagonistic 14.2% 15.0% 22.8% 19.4% 14.2% 19.4% 13.6% 5.4%
Horseshoe 50–500 Additive 14.0% 15.2% 24.4% 19.6% 14.0% 9.8% 20.0% 9.8%
Horseshoe 500–1500 Strong antagonistic 13.6% 11.8% 22.0% 17.4% 13.8% 21.8% 8.6% 1.4%
Horseshoe 500–1500 Mild antagonistic 10.0% 12.2% 22.8% 19.4% 9.8% 17.8% 11.0% 4.6%
Horseshoe 500–1500 Additive 12.4% 12.4% 21.6% 16.0% 12.2% 6.6% 17.4% 6.0%
Star 50–500 Strong antagonistic 16.2% 18.4% 14.4% 22.2% 17.4% 20.6% 6.0% 2.0%
Star 50–500 Mild antagonistic 15.0% 16.2% 17.8% 24.0% 17.6% 17.4% 6.4% 4.6%
Star 50–500 Additive 15.4% 14.2% 15.0% 23.0% 10.6% 10.4% 10.0% 10.4%
Star 500–1500 Strong antagonistic 11.2% 11.2% 9.6% 18.6% 14.6% 16.6% 2.2% 0.0%
Star 500–1500 Mild antagonistic 12.0% 12.2% 12.2% 18.6% 13.6% 11.4% 3.6% 1.6%
Star 500–1500 Additive 12.0% 12.6% 12.8% 18.6% 6.0% 8.0% 8.4% 8.0%
Notes: The first three columns indicate which of the 16 simulation scenarios the results on the corresponding row are representative of; columns 4 to 7 present the 
proportion of underestimates under the conventional MTC model for each of the above mentioned four comparative effects. Columns 8 to 11 present the proportion of 
underestimates under the fully additive MTC model.
Abbreviations: MTC, multiple treatment comparison; OR, odds ratio.
Here, the proportion of overestimates and underestimates 
were our chosen measures of statistical bias, and the coverage 
and power were our chosen measures of precision. We cal-
culated the above measures under the two considered MTC 
models, ie, the additive effects MTC model and the conven-
tional MTC model.
Results
Table 2 presents the proportion of overestimates associated 
with the four comparative OR (ORA,P, ORB,P, ORA+B,P, ORA+B,A) 
under the two models. Table 3 presents the proportion of 
underestimates. Table 4 presents the coverage of the 95% 
credible intervals associated with the four comparative 
OR under the two models. Lastly, Table 5 presents the 
power associated with each of (the statistical tests for) the 
comparative OR under the two models. Figures 2–5 display, 
as in the tables, the proportion of overestimates, proportion of 
underestimates, coverage, and power, respectively. However, 
the statistics displayed in Figures 2–5 are limited to the 
simulation scenarios where the trial sample sizes spanned 
from 500 to 1500.
In the additive scenarios, the proportions of overestimates 
with the additive model were consistently smaller or similar 
for all treatment comparisons when compared with the 
conventional model. In the mildly antagonistic scenarios, the 
effects of A + B versus A and A + B versus P yielded similar 
effects under the two models, whereas the effects of the single 
treatments (A versus P and B versus P) were less frequently 
overestimated under the additive model. In the strongly 
antagonistic scenarios, the effects of A + B versus A and 
A + B versus P were more frequently overestimated under 
the additive model.
In the additive scenarios, the proportions of underestimates 
with the additive model were consistently smaller or similar 
for all treatment comparisons when compared with the con-
ventional model. In particular, the comparison between A + B 
versus A, and also B versus P, were less frequently underes-
timated with the additive model. In the antagonistic scenarios 
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(and more pronounced in the strongly antagonistic scenarios), 
the comparisons A versus P and B versus P were more 
frequently underestimated with the additive model. However, 
the comparisons A + B versus P and A + B versus A remained 
less frequently underestimated with the additive model.
In the additive scenarios, the coverage of the two models 
was comparable, except for the full network with small 
sample size trials where the additive model performed 
slightly worse. Under the mildly antagonistic scenarios, 
the coverage of the two models was again comparable, 
except for the full network scenarios where the additive 
model performed worse. The coverage under the strongly 
antagonistic scenarios was comparable for the star and 
horseshoe networks, slightly worse for the additive model for 
the square network, and considerably worse for the additive 
model for the full network. However, it should be noted that 
the coverage for the comparison A + B versus P was similar 
for the two models in all scenarios.
In the additive scenarios, the additive model yielded 
considerably greater to similar power for all comparisons 
when compared with the conventional model. Under the 
mildly antagonistic scenarios, the additivity model yielded 
greater to similar power in most cases (the only exception 
being B versus P in the square network). Under the strongly 
antagonistic scenarios, the two models were comparable 
for the full and square networks (although B versus P had 
slightly lower power under the additive model), but under the 
horseshoe and star networks, the comparison A + B versus A 
had considerably more power under the additive model.
Discussion
It is common to provide combinations of individual drugs 
to patients. Therefore, it is important to assess the effect 
of a particular combination of drugs relative to that of the 
individual drugs themselves or to other combinations of 
interest. Comparative effectiveness can readily be evaluated 
with MTC, but the conventional modeling approach ignores 
dependencies between drug combinations (and single drugs) 
that include the same drug. The additive effects MTC model 
incorporates this dependency by assuming full additivity of 
Table 4 Coverage of 95% credible intervals for comparative intervention effect estimates (odds ratio estimates) of A versus P (OrA,P), 
B versus P (OrB,P), A + B versus P (OrA+B,P), and A + B versus A (OrA+B,A) under the two MTC models
Network  
type
Trial  
sample size
Interaction Coverage of 95% credible intervals
Conventional MTC model (model 1) Additive MTC model (model 2)
ORA,P ORB,P ORA+B,P ORA+B,A ORA,P ORB,P ORA+B,P ORA+B,A
Full 50–500 Strong antagonistic 95.8% 94.4% 95.6% 91.8% 86.0% 85.2% 96.0% 84.4%
Full 50–500 Mild antagonistic 95.2% 95.8% 97.0% 90.8% 90.6% 89.6% 96.8% 87.8%
Full 50–500 Additive 94.0% 94.0% 95.6% 91.0% 91.6% 94.4% 95.4% 94.4%
Full 500–1500 Strong antagonistic 96.2% 96.0% 97.4% 92.2% 85.0% 81.0% 97.6% 82.2%
Full 500–1500 Mild antagonistic 94.6% 95.6% 96.4% 84.6% 87.4% 88.6% 96.2% 88.6%
Full 500–1500 Additive 95.4% 95.0% 96.6% 91.6% 93.2% 90.2% 96.6% 90.2%
Square 50–500 Strong antagonistic 96.6% 96.0% 94.8% 93.6% 93.0% 92.4% 95.6% 92.4%
Square 50–500 Mild antagonistic 97.0% 98.2% 96.4% 95.8% 95.8% 94.0% 96.4% 95.2%
Square 50–500 Additive 96.8% 95.6% 92.8% 91.6% 94.6% 94.6% 93.2% 94.6%
Square 500–1500 Strong antagonistic 97.6% 97.0% 96.4% 93.4% 91.2% 91.8% 96.4% 91.8%
Square 500–1500 Mild antagonistic 97.6% 97.4% 96.4% 94.2% 94.8% 95.6% 96.2% 93.0%
Square 500–1500 Additive 95.4% 97.6% 96.6% 92.8% 95.0% 95.8% 96.6% 95.8%
Horseshoe 50–500 Strong antagonistic 97.0% 95.4% 94.4% 92.6% 97.6% 90.6% 94.8% 90.6%
Horseshoe 50–500 Mild antagonistic 97.2% 97.4% 96.6% 93.6% 97.0% 94.2% 95.6% 95.4%
Horseshoe 50–500 Additive 96.8% 97.2% 92.2% 92.6% 96.6% 95.4% 95.6% 95.4%
Horseshoe 500–1500 Strong antagonistic 96.8% 97.0% 94.6% 90.2% 97.0% 92.6% 94.2% 92.6%
Horseshoe 500–1500 Mild antagonistic 96.2% 96.6% 93.4% 89.4% 96.2% 93.0% 95.8% 93.4%
Horseshoe 500–1500 Additive 97.6% 97.8% 95.4% 92.6% 97.6% 95.2% 96.6% 95.2%
Star 50–500 Strong antagonistic 95.0% 95.8% 96.4% 95.8% 95.4% 95.2% 95.6% 95.2%
Star 50–500 Mild antagonistic 95.4% 94.2% 95.6% 95.2% 94.8% 94.2% 95.4% 92.0%
Star 50–500 Additive 95.2% 96.0% 94.0% 94.0% 93.6% 95.0% 95.0% 95.0%
Star 500–1500 Strong antagonistic 95.6% 95.4% 96.6% 96.0% 93.6% 93.4% 94.0% 93.4%
Star 500–1500 Mild antagonistic 95.8% 97.6% 95.4% 96.6% 95.6% 96.0% 95.8% 94.8%
Star 500–1500 Additive 96.4% 96.0% 96.0% 95.8% 96.4% 96.4% 94.2% 96.4%
Notes: The first three columns indicate which of the 16 simulation scenarios the results on the corresponding row are representative of; columns 4 to 7 present the coverage 
under the conventional MTC model for each of the above mentioned four comparative effects. Columns 8 to 11 present the coverage under the fully additive MTC model. 
Abbreviations: MTC, multiple treatment comparison; OR, odds ratio.
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treatment effects, and thereby gains often valuable precision. 
However, when the additivity assumption is violated, the 
additive effects model may yield biased effect estimates.
Our simulation study provides insight into the extent to 
which the additivity assumption may be violated, and the 
additive effects model will still provide a worthwhile trade-
off in precision gain versus model bias. The additive effects 
model is, not surprisingly, far superior to the conventional 
MTC model under full additivity. When there exists a mild 
but potentially important antagonistic interaction, neither 
of the two models seems better than the other. When there 
exists a strong interaction, the degree of bias that the additive 
effects model produces does not seem worth the trade-off in 
precision gain. Considering the results of the additive and 
mildly antagonistic scenarios, it stands to reason that the 
precision-bias trade-off will be in favor of the additive effects 
model for any scenario where the degree of antagonism lies 
anywhere between the two scenarios. Thus, it seems reason-
able to prefer the additive effects model in situations where 
the assumption of approximate additivity is sensible.
Our simulation study comes with a number of strengths 
and limitations. Our simulation parameters were informed 
by real MTC examples and can thus be assumed applicable 
to MTCs in chronic obstructive pulmonary disease, and 
most likely also to similar areas where treatments are used in 
combination. Being regular readers and authors of systematic 
reviews, we believe that the spectrum of treatment networks 
and parameter values chosen for our simulations represent 
a substantial proportion of published meta-analysis and 
multiple treatment comparisons. However, our simulations 
may lack generalizability with respect to the parameters that 
we did not vary. In this vein, we did not vary the degree of 
between-trial variation or the control group risk, and we did 
not vary the combination of treatment effects of A, B, and 
A + B or the interaction ratio. We limited our simulation to 
four treatment arms (two active treatments A and B). This 
design feature is both a strength and a limitation. It is a 
strength because it facilitates understanding of how the two 
MTC models work at the basic level and allows for simple 
interpretation of the results. It is a limitation because most   
Table 5 Power associated with comparative intervention effect estimates (odds ratio [Or] estimates) of A versus P (OrA,P), B versus P   
(OrB,P), A + B versus P (OrA+B,P), and A + B versus A (OrA+B,A) under the two MTC models
Network  
type
Trial  
sample size
Interaction Power
Conventional MTC model (model 1) Additive MTC model (model 2)
ORA,P ORB,P ORA+B,P ORA+B,A ORA,P ORB,P ORA+B,P ORA+B,A
Full 50–500 Strong antagonistic 63.4% 25.2% 62.0% – 66.2% 15.2% 61.4% –
Full 50–500 Mild antagonistic 59.8% 21.2% 78.4% 11.0% 75.0% 25.2% 78.4% 25.2%
Full 50–500 Additive 62.6% 23.0% 93.4% 25.2% 87.0% 42.0% 93.6% 42.0%
Full 500–1500 Strong antagonistic 73.0% 25.2% 72.6% – 72.8% 17.0% 71.8% –
Full 500–1500 Mild antagonistic 66.8% 25.2% 86.2% 12.8% 78.4% 33.0% 85.6% 32.8%
Full 500–1500 Additive 72.2% 28.0% 98.4% 30.2% 92.8% 49.0% 98.4% 49.0%
Square 50–500 Strong antagonistic 38.8% 16.2% 35.4% – 33.0% 9.8% 33.6% –
Square 50–500 Mild antagonistic 42.6% 14.6% 41.0% 5.0% 41.0% 9.4% 41.2% 9.4%
Square 50–500 Additive 45.8% 15.4% 65.8% 16.0% 62.6% 20.0% 67.4% 20.0%
Square 500–1500 Strong antagonistic 48.0% 14.8% 40.0% – 42.8% 10.8% 40.6% –
Square 500–1500 Mild antagonistic 50.6% 19.4% 55.4% 7.4% 50.6% 14.0% 56.6% 14.0%
Square 500–1500 Additive 53.4% 16.0% 75.4% 18.6% 71.0% 22.8% 77.2% 22.6%
Horseshoe 50–500 Strong antagonistic 31.2% 12.8% 20.4% – 31.0% 9.8% 34.8% –
Horseshoe 50–500 Mild antagonistic 31.8% 10.2% 25.0% 7.2% 32.2% 11.6% 41.0% 11.6%
Horseshoe 50–500 Additive 31.8% 11.0% 37.4% 15.4% 33.6% 21.8% 49.8% 21.8%
Horseshoe 500–1500 Strong antagonistic 35.6% 12.6% 21.6% – 33.8% 10.6% 41.6% –
Horseshoe 500–1500 Mild antagonistic 36.6% 9.4% 31.2% 8.2% 36.8% 13.8% 48.2% 13.8%
Horseshoe 500–1500 Additive 36.2% 10.2% 46.4% 19.2% 36.0% 24.6% 58.6% 24.6%
Star 50–500 Strong antagonistic 37.8% 13.0% 36.2% – 37.0% 9.2% 67.2% –
Star 50–500 Mild antagonistic 34.8% 15.6% 48.4% 3.4% 38.8% 16.2% 74.4% 16.2%
Star 50–500 Additive 39.4% 14.2% 75.0% 8.2% 55.4% 21.4% 89.8% 21.4%
Star 500–1500 Strong antagonistic 48.2% 17.2% 50.6% – 50.4% 12.2% 82.4% –
Star 500–1500 Mild antagonistic 45.4% 14.0% 64.8% 3.4% 56.2% 15.2% 87.0% 15.2%
Star 500–1500 Additive 48.8% 17.0% 83.4% 11.8% 65.0% 23.6% 95.2% 23.6%
Notes: The first three columns indicate which of the 16 simulation scenarios the results on the corresponding row are representative of; columns 4 to 7 present the power 
under the conventional MTC model for each of the abovementioned four comparative effects, and columns 8 to 11 present the power under the fully additive MTC model. 
No power is reported for OrA+B,A under simulation scenarios with strong antagonistic interactions because there is no difference between A + B and A in this scenario.
Abbreviations: MTC, multiple treatment comparison; OR, odds ratio.
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Figure 2 Proportion of overestimates for comparative intervention effects estimates (Or estimates) of A versus P (Or A), B versus P (Or B), A + B versus P (Or AB), and 
A + B versus A (Or AB,A) under the two MTC models. 
Notes: The black bars indicate the proportion of overestimates under the conventional model (model 1) and the gray under the additive effects model (model 2). The Or 
parameters are ordered by row, the treatment network type by column, and the degree of additivity/antagonism by row within each sideways bar plot.
Abbreviation: Or, odds ratio.
Additive
O
R
 
A Mildly
antagonistic
Strongly
antagonistic
Additive
O
R
 
B Mildly
antagonistic
Strongly
antagonistic
Additive
O
R
 
A
B Mildly
antagonistic
Strongly
antagonistic
Additive
O
R
 
A
B
,
A
Mildly
antagonistic
Strongly
antagonistic
05 10 15 20 25 05 10 15 20 25 05 10 15 20 25 05 10 15 20 25
Conventional Additive
Full Square Star Horseshoe
Figure 3 Proportion of underestimates for the comparative intervention effects estimates (Or estimates) of A versus P (Or A), B versus P (Or B), A + B versus P (Or AB), 
and A + B versus A (Or AB,A) under the two MTC models. 
Notes: The black bars indicate the proportion of underestimates under the conventional model (model 1) and the gray under the additive effects model (model 2). The Or 
parameters are ordered by row, the treatment network type by column, and the degree of additivity/antagonism by row within each sideways bar plot.
Abbreviation: Or, odds ratio.
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Figure 4 Presents the coverage of the 95% credible intervals associated with the comparative intervention effects estimates (Or estimates) of A versus P (Or A), B versus P   
(Or B), A + B versus P (Or AB), and A + B versus A (Or AB,A) under the two MTC models. 
Notes: The black bars indicate the coverage under the conventional model (model 1) and the gray under the additive effects model (model 2). The Or parameters are 
ordered by row, treatment network type by column, and degree of additivity/antagonism by row within each sideways bar plot.
Abbreviation: Or, odds ratio.
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Figure 5 Presents the power with the comparative intervention effects estimates (Or estimates) of A versus P (Or A), B versus P (Or B), A + B versus P (Or AB), and 
A + B versus A (Or AB,A) under the two MTC models. 
Notes: The black bars indicate the power under the conventional model (model 1) and the gray under the additive effects model (model 2). The Or parameters are ordered 
by row, treatment network type by column, and degree of additivity/antagonism by row within each sideways bar plot.
Abbreviation: Or, odds ratio.
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MTCs are performed on larger networks where several 
drugs may be combined, and potentially, several interactions 
may occur. We discuss the implications of this in more 
detail below.
As mentioned above, most MTCs are performed on larger 
treatment networks. In respirology or other medical areas, this 
may involve several drug combinations. Typically, only a few 
of all possible drug combinations will have been compared in 
head-to-head randomized clinical trials, and perhaps equally 
infrequent, most individual drugs and drug combinations 
cannot be compared indirectly. For example, if three active 
drugs A, B, and C, and all possible combinations thereof, are 
considered in an MTC, a situation can occur where A + B 
and A + C have been compared with placebo or any of the 
individual drugs A, B, and C, but B + C and A + B + C have 
not. In this situation, the conventional MTC model would not 
allow for estimation of comparative effectiveness between 
B + C or A + B + C and any of the other interventions. How-
ever, the additive effects of the MTC model would allow for 
estimation of such comparative effects. We could refer to such 
estimates as “fully additive estimates”. Whether and when 
it is sensible to combine evidence in such a manner is dis-
cussed elsewhere, and the decision to combine such evidence 
will typically depend on more than statistical factors. Our 
simulations demonstrate the statistical soundness of deriving 
additive effect estimates in the absence of direct comparisons. 
Checking that other necessary clinical and biological criteria 
are met will confirm that at least ‘approximate additivity’ 
holds true.13 With this, authors of MTCs can be comfortable 
in statistically combining direct and indirect evidence with 
and additive effects MTC model.
In conclusion, the additive MTC model is statistically supe-
rior when additivity holds true, and comparably advantageous 
in terms of its bias-precision trade-off when additivity is mildly 
violated. This suggests that the additive effects MTC model 
can readily be used in situations where one can only assert 
approximate additivity.
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